Liver Unit, Department of Gastroenterology, Tel Aviv Medical Center, Tel Aviv, Israel; School of Public Health, Faculty of Social Welfare and Health Sciences, University of Haifa, Haifa, Israel.
Division of Gastroenterology, Ospedale di Acireale, Azienda Sanitaria Provinciale di Catania, Catania, Italy.
Transl Res. 2015 Mar;165(3):428-36. doi: 10.1016/j.trsl.2014.10.008. Epub 2014 Oct 17.
Retrospective studies suggest that coffee consumption may exert beneficial effects in patients with nonalcoholic fatty liver; however, prospective data supporting a protective role on liver steatosis development are lacking. In this study, we aimed to evaluate the association between coffee consumption and fatty liver onset in the general population. The analysis was performed both in a cross-sectional cohort (n = 347) and, prospectively, in a subcohort of patients without fatty liver at baseline and followed-up for 7 years (n = 147). Fatty liver was diagnosed with abdominal ultrasound and liver steatosis was quantified noninvasively by hepatorenal index (HRI) and SteatoTest, whereas FibroTest was used to assess fibrosis degree. A structured questionnaire on coffee consumption was administrated during a face-to-face interview. Neither the incidence nor the prevalence of fatty liver according to ultrasonography, SteatoTest, and the HRI was associated with coffee consumption. In the cross-sectional study, high coffee consumption was associated with a lower proportion of clinically significant fibrosis ≥ F2 (8.8% vs 16.3%; P = 0.038); consistently, in multivariate logistic regression analysis, high coffee consumption was associated with lower odds for significant fibrosis (odds ratio = 0.49, 95% confidence interval, 0.25-0.97; P = 0.041) and was the strongest predictor for significant fibrosis. No association was demonstrated between coffee consumption and the new onset of nonalcoholic fatty liver, but coffee intake may exert beneficial effects on fibrosis progression.
回顾性研究表明，咖啡的摄入可能对非酒精性脂肪肝患者有益；然而，目前缺乏支持咖啡摄入对肝脂肪变性发展具有保护作用的前瞻性数据。在本研究中，我们旨在评估咖啡摄入与普通人群中脂肪肝发病的关系。该分析在横断面队列（n=347）和前瞻性亚队列中进行，亚队列中患者在基线时无脂肪肝，并随访 7 年（n=147）。通过腹部超声诊断脂肪肝，通过肝肾功能指数（HRI）和 SteatoTest 无创性量化肝脂肪变性，而 FibroTest 用于评估纤维化程度。通过面对面访谈进行了关于咖啡摄入的结构化问卷调查。根据超声、SteatoTest 和 HRI，咖啡摄入量与脂肪肝的发生率或患病率均无相关性。在横断面研究中，高咖啡摄入与临床显著纤维化（≥F2）的比例较低相关（8.8% vs. 16.3%；P=0.038）；同样，在多变量逻辑回归分析中，高咖啡摄入与显著纤维化的几率较低相关（比值比=0.49，95%置信区间，0.25-0.97；P=0.041），是显著纤维化的最强预测因子。咖啡摄入与非酒精性脂肪性肝病的新发无关，但咖啡摄入可能对纤维化进展有有益影响。
